Delivery Science teams up with URI for testing services

By Staff Reporter

- Last updated on GMT

Related tags Pharmacology

US contract polymer maker Delivery Science has ramped up its formulation and analytical testing offering in a partnership with the University of Rhode Island’s (URI) College of Pharmacy.

Under the accord, showcased at AAPS 2009 in Los Angeles, researchers develop polymer-drug formulations that can be produced using hot melt extrusion, with a particular focus on improving delivery characteristics.

In practice, Delivery Science determines the chemical properties, thermal characteristics and optimal delivery route of a particular polymer/ active pharmaceutical ingredient (API) combination, at which point URI conducts analytical testing.

Company managing director Tony Listro said that URI’s analyses, primarily dissolution and stability assessments, will focus on further optimising the drug formulation.

The tests determine whether the active is present in and stable in formulation​,” explained Listro, adding that: “they also determine the dissolution and release properties of the drug, whether or not any degradants are formed​”.

Once all the relevant data has been gathered Delivery Science blends and extrudes the mixture in batches suitable for clinical assessment at its current good manufacturing practices (cGMP) facility in Putnam, Connecticut.

Listro said that the aim of the partnership is to industry clients a faster path through the drug development process and added that working with URI is a “natural extension of Delivery Science’s development capabilities and services.”

Dave Worthern, visiting assistant professor of biomedical and pharmaceutical services at URI, was also positive about the collaboration, explaining that it has already made considerable progress.

“[The partnership] has led to developments in basic and applied sciences, educational opportunities and student internships in a hands-on, real world setting [as well as] breakthroughs in product development and global health issues.”

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us